Momenta Phama (MNTA) Lower; FDA Approves Generic Lovenox (TEVA)

Momenta Phama (NASDAQ: MNTA) is lower today after the FDA approved the generic version of Lovenox.

According to the FDA website, Teva's enoxaparin sodium was approved on June 23, 2014. More information about the drug can be found here.

Momenta is down 5.2 percent.

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Keenova doses first patient in Phase 3 hammer toe drug trial
• AbbVie lung cancer drug data shows high response rates at WCLC 2026